Eiger BioPharmaceuticals adds two to senior management team

Jim Welch joins as Chief Financial Officer and Jim Shaffer as Chief Business Officer

Eiger BioPharmaceuticals, a privately owned Californian biopharmaceutical company developing therapies for orphan diseases, has appointed James Welch as Chief Financial Officer and James Shaffer as Chief Business Officer.

Prior to joining Eiger, Welch was Chief Financial Officer and Secretary of Virobay Incorporated. He was also Chief Financial Officer of Acelrx Pharmaceuticals, Chief Financial Officer and Corporate Secretary at Cerimon Pharmaceuticals, Chief Financial Officer and Corporate Secretary at Rigel Pharmaceuticals, and earlier in his career was Chief Financial Officer of Biocircuits diagnostics.

Shaffer was previously Vice President and Chief Commercial Officer at Halozyme Therapeutics. He was also Executive Vice President and Chief Commercial Officer at Clinical Data, which was acquired by Forest Labs. He has also worked at New River Pharmaceuticals as Vice President of Commercial Operations, in addition to Prestwick Pharmaceuticals, InterMune, GlaxoSmithKline and Merck.

You may also like

Pharmaceutical

Eiger Bio strengthens senior management team

By hiring Debra Odink as Senior Vice President of Technical Operations
Finance

Eiger BioPharmaceuticals closes merger with Celladon

The US firm is developing a clinical stage pipeline of orphan disease programmes
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Can creative carriers deliver the goods?

There are many reasons why conventional drug delivery technologies may not be effective and a more creative approach is required to convey the active ingredient to its destination. Dr Sarah Houlton looks at the more promising technologies in development
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Subscribe now